At-equity investees’ higher contribution
19/11/23 -"We have updated our model at the at-equity associates line as it looks as if Vifor Fresenius Medical Care Pharma (JV with former Galenica / CSL Vifor) makes greater contributions due to higher sales ..."
Pages
56
Language
English
Published on
19/11/23
You may also be interested by these reports :
10/10/24
We have trimmed our valuations to factor in a slower-than-anticipated recovery in the bioprocessing business, as end-customer inventory ...
07/10/24
Since we last teased on the vertically-integrated (acting as innovator, manufacturer, wholesaler and retailer) hearing care giant Sonova’s (Add; ...
04/10/24
Finally, a confirmation of the FY EBITDAR guidance, supported by the as-anticipated H1 figures, along with an accelerated asset disposal programme, ...
03/10/24
Despite some moderation to our near-term estimates, we have raised our target price by c.8%, which is a combination of a healthy upgrade in the DCF ...